Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.60
+0.23 (1.86%)
At close: May 22, 2026, 4:00 PM EDT
12.54
-0.06 (-0.49%)
After-hours: May 22, 2026, 7:54 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 377 employees as of December 31, 2025. The number of employees decreased by 26 or -6.45% compared to the previous year.
Employees
377
Change (1Y)
-26
Growth (1Y)
-6.45%
Revenue / Employee
$175,310
Profits / Employee
-$1,046,674
Market Cap
1.76B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 377 | -26 | -6.45% |
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Lakefront Biotherapeutics NV | 558 |
| Vericel | 398 |
| Ocular Therapeutix | 325 |
| Nurix Therapeutics | 317 |
| Syndax Pharmaceuticals | 298 |
| Harmony Biosciences Holdings | 293 |
| Stoke Therapeutics | 170 |
NTLA News
- 5 days ago - Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 12 days ago - Intellia Therapeutics price target raised to $17 from $13 at Bernstein - TheFly
- 12 days ago - Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright - TheFly
- 13 days ago - Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 13 days ago - Intellia Therapeutics price target lowered to $19 from $20 at BofA - TheFly
- 13 days ago - Intellia Therapeutics price target lowered to $49 from $58 at Canaccord - TheFly
- 14 days ago - Intellia Therapeutics reports Q1 EPS (81c), consensus (90c) - TheFly
- 14 days ago - Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - GlobeNewsWire